YUE DA INTERNATIONAL HOLDINGS LIMITED
悅達國際控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 629)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR, CHAIRMAN OF REMUNERATION COMMITTEE AND MEMBER OF AUDIT COMMITTEE AND NOMINATION COMMITTEE AND COMPLIANCE WITH THE LISTING RULES

The Board is pleased to announce that Dr. Wang Li was appointed as an independent non-executive Director of the Company, the chairman of the remuneration committee and a member of the audit committee and nomination committee with effect from 14 August 2026.

Reference is made to the announcements of Yue Da International Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") dated 15 May 2026 and 15 June 2026 in relation to, among other things, non-compliances with Rule 3.10(1), Rule 3.10A, Rule 3.21, Rule 3.25, Rule 3.27A and Rule 13.92(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**"), relating to, among other things, an insufficient number and proportion of independent non-executive Directors, the audit committee of the Company (the "**Audit Committee**") does not meet the requirements of Rule 3.21, the remuneration committee of the Company (the "**Remuneration Committee**") does not meet the requirements of Rule 3.25, and the nomination committee of the Company (the "**Nomination Committee**") does not meet the requirements of Rule 3.27A.

The board (the "**Board**") of directors (the "**Directors**") of the Company hereby announces that Dr. Wang Li ("**Dr. Wang**") was appointed as an independent non-executive Director, the chairman of the Remuneration Committee and a member of the Audit Committee and the Nomination Committee with effect from 14 August 2026.

Set out below are the biographical details of Dr. Wang.

Dr. Wang, aged 69, holds a Bachelor of Pharmacy degree from Sichuan Medical College, was a visiting scholar at the Faculty of Medicine, Nagoya University, and a Doctor of Pharmacy degree from Hokuriku University. She has been engaged in pharmacological and toxicological research for over 40 years. She was formerly a professor and doctoral supervisor at West China Hospital of Sichuan University, and is currently the chief scientist of Chengdu Huaxi Haiqi Pharmaceutical Technology Co., Ltd./National Chengdu New Drug Preclinical Safety Evaluation Center and the chief scientist of Chengdu Haifeng Biotechnology Co., Ltd. After graduating from Sichuan Medical College in 1982, Dr. Wang stayed on to work at the university. She obtained her PhD in Pharmacy from Hokuriku University in 1997. From 1990 to 2001, she was a special foreign researcher at Nagoya

University School of Medicine, conducting research on disease pathogenesis and clinical quantitative pharmacology. In 2001, after returning to China, she was invited by West China Hospital to lead the establishment of a new preclinical safety evaluation center for new drugs. Dr. Wang has received the second prize of the National Science and Technology Progress Award and the first prize of the Ministry of Education Science and Technology Progress Award. In 2017, Dr. Wang was awarded the title of National March 8th Red Banner Pacesetter, and in 2023, she was selected as one of Sichuan's Top Ten Scientific and Technological Innovation Figures of the Year.

Save as disclosed above, as at the date of this announcement, Dr. Wang confirms that she (i) does not have any relationship with any Director, senior management, chief executive, substantial or controlling shareholder of the Company and holds no other positions within the Company and other members of the Group; (ii) does not have nor is deemed to have any interest in the shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (iii) does not hold any other directorships in any other public companies, the securities of which are listed on any securities market in Hong Kong or overseas, in the last three years up to the date of this announcement.

The Company entered into a letter of appointment with Dr. Wang for a term of three years commencing on 14 August 2026, which will be automatically renewed unless otherwise agreed by the Company and Dr. Wang in writing or until her appointment is terminated in accordance with the provisions thereto. She will hold office as an independent non-executive Director until the Company's first annual general meeting after her appointment and will be subject to re-election at such meeting pursuant to the articles of association of the Company (the "**Articles**"). Thereafter, Dr. Wang's directorship is subject to the provisions of retirement by rotation and re-election of Directors under the Articles. Dr. Wang is entitled to an annual director's fee of RMB100,000 which is determined with reference to her experience and duties as well as prevailing market conditions. Her remuneration is subject to review by the Board and the Remuneration Committee from time to time.

Dr. Wang has confirmed (i) her independence as regards each of the factors set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) she does not have, and has not had, any financial or other interest in the business of the Group, nor any connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence as at the time of his appointment.

Save as disclosed above, there are no other matters or information that need to be brought to the attention of shareholders of the Company or to be disclosed pursuant to Rules 13.51(2) of the Listing Rules in relation to the aforesaid appointment.

The Board would like to express its warm welcome to Dr. Wang to the Board.

COMPLIANCE WITH THE LISTING RULES

Following the appointment of Dr. Wang as an independent non-executive Director, the chairman of the Remuneration Committee and a member of the Audit Committee and Nomination Committee, along with the earlier appointment of Ms. Tang Lo Nar as an independent non-executive Director and as chairman of the Audit Committee on 15 June 2026, the Company has fully re-complied with the requirements of Rule 3.10(1), Rule 3.10A, Rule 3.21, Rule 3.25, Rule 3.27A and Rule 13.92(2) of the Listing Rules.

By order of the Board
Yue Da International Holdings Limited
Ji Hulin
Chairman and Executive Director

Hong Kong, 14 August 2026

As at the date of this announcement, the Board comprises the following members: (a) as executive Directors, Mr. Ji Hulin, Mr. Xue Zhicheng, Mr. Pan Mingfeng and Dr. Teng Songsong (b) as non-executive Director, Mr. Yan Bingde; and (c) as independent non-executive Directors, Dr. Liu Yongping, Ms. Tang Lo Nar and Dr. Wang Li.

If there is any inconsistency in this announcement between the Chinese and English versions, the English version shall prevail.